Ponesimod Linked to Low Levels of Disease Activity in Relapsing Multiple Sclerosis
No new safety signals were observed in the combined analysis of ponesimod from the phase 2b core study and extension study.
Mark Freedman, MD
Data from a phase 2b core study (NCT01006265) and its extension study (NCT01093326) revealed that long-term treatment with ponesimod (Janssen Pharmaceutical) 20 mg resulted in consistently low levels of disease activity across relevant clinical and magnetic resonance imaging (MRI) outcomes in patients with relapsing-remitting multiple sclerosis (RRMS).1
Among a cohort of 214 patients who were still on ponesimod treatment, annualized relapse rates (AARs) for confirmed relapses in those who were in the 20-mg group were 0.154 (95% CI, 0.111–0.214), with 64.1% of patients remaining free of confirmed relapse.
Presented at MS Virtual 2020, the 8th joint ECTRIMS-ACTRIMS meeting, September 11–13, 2020, and led by Mark Freedman, MD, director, multiple sclerosis research unit, Ottawa Hospital, the data showed that Kaplan-Meier estimate of 6-month confirmed disability accumulation (CDA) at week 432 was 20.4% (95% CI, 13.7–29.7) for those treated with ponesimod.
A total of 435 patients with RRMS received >1 dose of ponesimod (10-, 20-, or 40-mg per day) during the core and/or extension study, but investigators subsequently discontinued the 40- and 10-mg doses during treatment period 1 (TP1) and TP2 of the extension study. Patients then received either 10 or 20 mg during TP2, followed by open-label 20 mg in TP3.
MRI outcomes showed a mean number of 0.448 (95% CI, 0.305–0.657) T1 gadolinium-enhancing lesions per patient per scan, as well as a mean number of 0.718 (95% CI, 0.523–0.985) for new or enlarging T2 lesions per year.
Treatment with ponesimod did not show any new safety signals, with nasopharyngitis (30%), headache (24%) and upper respiratory tract infection (21%) representing the most common treatment-emergent adverse events (TEAEs). Most of the serious adverse events (SAEs) were reported in a single patient and no SAE was reported at an incidence of >1%.
The median exposure to the 20-mg ponesimod was 8.02 years and the cumulative exposure across all doses was 2372.47 patient-years.
Ponesimod, a selective sphingosine 1-phosphate receptor-1 (S1P) modulator, has been known to show its clinical relevance in the phase 3 OPTIMUM study (NCT02425644), which had data presented at both the American Academy of Neurology (AAN) 2020 Annual Meeting and ECTRIMS 2019.
In that study, ponesimod was found to be superior to teriflunomide (Aubagio; Sanofi) in terms of ARRs, fatigue symptoms, MRI activity, brain atrophy and evidence of disease activity. They also found no differences between the treatments on 12-week and 24-week confirmed disability accumulation estimates.2,3
The respective ponesimod versus teriflunomide findings for the mean number of combined unique active lesions per year (CUALs) per year on MRI were 1.405 for the ponesimod group versus 3.164 for the teriflunomide group (relative rate reduction, 56%; P <.0001). Brain volume loss at Week 108 for the ponesimod and teriflunomide groups respectively were −0.91% and −1.25% (reduced by 0.34% points; P <.0001), while no evidence of disease activity (NEDA) was achieved in 25.0% and 16.4% of patients, respectively (odds ratio [OR], 1.70; P = .0004).
Results from OPTIMUM led Janssen to submit its new drug application (NDA) for ponesimod forthe treatment of adults with relapsing MS in March. The company did not announce a prescription user drug fee act (PDUFA) date or when they would hear back from the FDA on the NDA.4
For more coverage of ECTRIMS-ACTRIMS, click here.
